Onconova Therapeutics Inc (ONTX.OQ)
13 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2006||Chairman of the Board|
|59||1998||President, Chief Executive Officer, Director|
|47||2016||Chief Financial Officer|
|64||2015||Senior Vice President - Research and Development, Chief Medical Officer|
|52||2005||Senior Vice President - Product Development|
- BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
- BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor
- BRIEF-Onconova Therapeutics prices public offering
- BRIEF-Onconova Therapeutics reports Q3 revenue $100,000
- BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics